1. A JR is an academic session in which we go through selected article summaries over 60-75 min.
2. It takes place every Monday and Thursday via our JR Discord channel โ see calendar.
3. Its purpose is to:
- Understand the main messages from the summarized articles.
- Recall pivotal concepts pertinent to our clinical practice.
- Train clinical reasoning by connecting key concepts to real-life scenarios.
4. The articles are chosen during the session from a curated, labeled, and codified list of remarkable summarized articles.
5. We take interactive and pedagogic notes in a shared document, using visual aids, highlighting, underlining, arrows, and conceptual links to connect ideas and facilitate understanding.
6. For each session, we create RECAP key points and publish them on our website.
7. In the following session, we briefly recall the previous JRโs RECAP to reinforce learning through retrieval practice.
๐ซ๐ฝ = abdomen = abdominal, ๐ค = analysis, ๐ = arrhythmia, ๐ฉธ = blood = hematology, ๐ง = brain, โก๏ธ = cardiac arrest, โญ๏ธ = circulation, โ = decrease, ๐๐ซ = exclusion, ๐จ = flow, ๐ซ = heart, โ๏ธ = improve, ๐๐ก = inclusion, โ = increase, ๐ฅ = inflammation, ๐ชฒ = infections, โพ๏ธ = kidneys = renal, โธ = liver = hepatic, ๐ซ = lungs, ๐ช๐ฝ = muscle, โฐ = pressure, ๐ณ๏ธ = prevention, โ = recommendation(s), โ๐ฝ = stop, ๐ฃ = suggestion(s), โ๏ธ = worsen, CIpxs = critically ill patients, DX = diagnosis, h_LOS = Hospital length of stay, icu_LOS = ICU length of stay, inc_ = incident, MA = metaanalysis, mc = multicentric, MM = mortality, MM90 = mortality at 90 days, pOC = primary outcome(s), pxs = patients, RCT = randomized controlled trial, sOC = secondary outcome(s), sr = systematic review, SS = survival, w_ = with, wo_ = without, yo = years old.
๐๐๐พ ๐จ๐๐ค๐ฅ๐ โ Y, J, C โ T โ N โ t โ P I C O:
Monday, September 14, 2026 at 18:01:58 CEST
EQO, BKN, C, KYEC, LP, HIBN, AAQC
2026 NEJMc - A New Guideline on CardiovascularโKidneyโMetabolic Syndrome (AHA).pdf
Codified by ๐๐๐ผ๐ผ๐๐พ แดฎแดผ (LCO)
Glossary: ACC = American College of Cardiology, ADA = American Diabetes Association, AHA = American Heart Association, ASN = American Society of Nephrology, CKD = chronic kidney disease, CKM = cardiovascular-kidney-metabolic syndrome, CVD = cardiovascular disease, HF = heart failure, T2D = type 2 diabetes
1. ๐๐๐พ ๐จ๐๐ค๐ฅ๐ โถ๏ธ Y, J, C โ T โ N โ t โ P I C O:
2. 2026, CIRCULATION, USA ๐บ๐ธ โ GL โ NA โ โ โ P I C O:
3. EVIDENCE.
a. CKD risk categories (KDIGO)
b. Prediabetes CRITERIA 2026 (ADA)
c. T2D criteria (ADA)
d. CKD definition - KDIGO 2021
4. METHODS.
- Obesity ๐งธ
- T2D ๐ซ
- CKD โพ๏ธ
- CVD ๐ซ
5. RESULTS.
a. 4 stages
i. 1. overweight โ obesity โ prediabetes
ii. 2. HTA โ T2D โ mod-hr_CKD
iii. 3. subclinical CVD (calcifications โ pre-HF) โ โฅ20% (r_10y of CVD) PREVENT calculator โ hr_CKD
iv. 4. Clinical CVD w_CKM conditions
b. PREVENT โ 10-30y r_ASCVD, total CVD, HF
c. Monitoring:
i. 2-3y, S1:
1. lipids
2. glycemia
3. eGFR
ii. 1y, other S:
iii. UACR โ 1y at โฅS2
โณ TIME MANAGEMENT
02:27:28
Round: 6 00:55:42 Comments
Round: 5 02:05:13 RECAP
Round: 4 09:20:02 Interpretation
Round: 3 03:35:38 Reading + notes
Round: 2 04:31:72 ART selectionRound: 1 03:52:22 Past JR
d. Overweight + obesity โ CONSIDERED root cause of CKM
i. AGGRESIVE lifesyle modification
ii. pharmacologic TTO (selected pxs)
6. RATIONALE.
a. We should know the NEW FRAMEWORK
b. Tan Y, Wu Y, Ding X, et al. A prospective cohort study on the
c. Li N, Li Y, Cui L, et al. Association between different stages of cardiovascular-kidney-metabolic syndrome and the risk of all-cause mortality. Atherosclerosis. 2024;397:118585. doi:10.1016/j.atherosclerosis.2024.118585
d. Li J, Wei X. Association of cardiovascular-kidney-metabolic syndrome with all-cause and cardiovascular mortality: A prospective cohort study. Am J Prev Cardiol. 2025;22:100985. Published 2025 Mar 29. doi:10.1016/j.ajpc.2025.100985
7. SOURCE โถ๏ธ Ndumele CE, et al. AHA/ACC/ADA/ASN guideline for the prevention, detection, evaluation, and management of cardiovascularโkidneyโmetabolic syndrome: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2026 Jun 9; 2026; [e-pub]. DOI: 10.1161/CIR.0000000000001453. PubMed
Monday, September 10, 2026 at 19:07:23 CEST
EQO, BKN, C, KYEC, LP, HIBN, AAQC
2026 NEJMc - Antibiotics and the Gut Microbiome(Nat Med).pdf
Codified by YAPG
Glossary: CVD = cardiovascular DIS, DIS = diseases, DM = diabetes, l-t = long-term.
1. ๐๐๐พ ๐จ๐๐ค๐ฅ๐ โถ๏ธ Y, J, C โ T โ N โ t โ P I C O:
2. 2026, Nat Med, SW โ ๐ค pros_SURVEILL studies โ 15k โ 8y โ P I C O:
3. EVIDENCE.
a. ATBs โ reliably wreak havoc โฉ gut microbiome
b. Duration is unknown (systematically)
4. RESULTS.
- deep-vein thrombosis
- hemoptysis
- PE as most likely DX
โณ TIME MANAGEMENT
37:54:51
Round: 5 02:19:54 Comments
Round: 4 14:06:68 RECAP
Round: 3 17:26:47 โ
Round: 2 02:39:89 Reading + notes
Round: 1 01:21:92 ART selection
5. RESULTS.
a. Frequency ๐ พ
i. YEARS < โ 1,8%
ii. CTPA > โ 5,5%
b. Avoid CTPA
i. 22%
6. RATIONALE.
a. Safe always w_D-DIMER.
b. Editorialists โ might NOT APPLY:
i. โ thrombogenic CA
ii. pancreatic
iiii. hepatobiliary
c. In other types of CA โ avoid CTPA and OK YEARS only.
7. SOURCE โถ๏ธ Akerboom B, et al. YEARS algorithm for diagnosis of suspected pulmonary embolism in patients with cancer: A randomized clinical trial. JAMA 2026 Jul 12; [e-pub]. DOI: 10.1001/jama.2026.10676. PubMed
8. SOURCE โถ๏ธ Han HB, Beckman JA. Ruling Out PE in Cancer โ Can YEARS Reduce CT Imaging? JAMA 2026 Jul 12; [e-pub]. DOI: 10.1001/jama.2026.12480. PubMed
Codified by ๐๐๐ผ๐ผ๐๐พ แดฎแดผ (EQO)
Glossary: CBC = complete blood count, CKD = chronic kidney disease, DEF = definition, ESAs = erythropoiesis-stimulating agents, Sโ = stroke, TSAT = transferrin saturation, TTO = treatment(s)
1. ๐๐๐พ ๐จ๐๐ค๐ฅ๐ โถ๏ธ 2026, KI, โ โ GL โ NA โ NA โ P I C O:
2. EVIDENCE.
a. GL โ sr w_evidence appraisal โ Expert opinion โ PRACTICE POINTS
b. Last GL on anemia โ a DECADE ago
c.
Thursday, September 17, 2026 at 18:20:58 CEST
EQO, BKN, C, KYEC, LP, HIBN, AAQC
โณ TIME MANAGEMENT
01:39:14
Round: 6 00:35:85 Comments
Round: 5 32:23:32 RECAP
Round: 4 26:27:00 Interpretation
Round: 3 04:31:48 Reading + notes
Round: 2 05:38:91 ART selection
Round: 1 29:37:99 Past JR
3. DX โ EVAL.
i. CBC
ii. reticulocytes
iii. ferritin
iv. TSAT
i. 1x a YEAR โ S3
ii. 2X a YEAR โ S4
iii. 4x a YEAR (every 3m) โ S5
i. โ Hb <12
ii. โ๏ธ Hb <13
iii. <15yo โ age-specific thresholds
i. Ferritin <45ng/mL OR
ii. microcytic anemia
5. Fe โ โ supplementation.
a. IRON:
i. HD
1. ferritin โค500 โ TSAT โค30
ii. wo_HD
1. ferritin โค100 โ TSAT โค40, OR
2. ferritin 100-300 โ TSAT โค25
b. w_Fe therapy, monitor:
i. CBC
ii. ferritin
iii. TSAT
c. w_Fe therapy, frequency:
i. HD โ every 1-3m
ii. wo_HD โ every 3m
d. โ๏ธ Fe in SYSTEMIC INF
6. Anemia MEDS
a. ESAs when Hb โค9-10
i. HD
ii. peritoneal dyalysis
b. Better ESAs than โhypoxia-inducible factorโprolyl hydroxylase inhibitorsโ
c. wo_dialysis โฉ INDIVIDUALIZE (symptoms โ harm-benefit)
d. Target Hb <11,5
i. Sโ risk
e. โ๏ธ ESAs โ r_thromboembolic (d_acute Sโ )
7. RATIONALE
a. Expert opinion or low-certainty evidence.
b. Diligent โ Fe supplementation in CKD
c. Unnecessary supplementation?
d. Clinical judgement GUIDES TTO decision.
8. SOURCE โถ๏ธ Babitt JL, et al. Executive summary of the KDIGO 2026 Clinical Practice Guideline for the management of anemia in chronic
kidney disease (CKD). Kidney Int 2026 Jan; 109:44. DOI: 10.1016/j.kint.2025.06.005.
2026 NEJMc - Acute Coronary Syndromes in Premenopausal โ (C).pdf
Codified by KYEC
ACS = acute coronary syndrome, DAPT = dual antiplatelet therapy, ID = identify, MECHs = mechanisms, MINOCA = myocardial infarction with nonobstructive coronary arteries, mm = management, PCI = percutaneous coronary intervention, rf = risk factor(s), SAP = systolic arterial pressure, SCAD = spontaneous coronary artery dissection, TTO = treatment(s)
1. ๐๐๐พ ๐จ๐๐ค๐ฅ๐ โถ๏ธ 2026, CIRCULATION, USA ๐บ๐ธ โ GL โ NA โ NA โ P I C O:
2. EVIDENCE.
a. ACS โ distinct + understuded + w_unique etiologieS
b. Nonobstructive + nonatherosclerotic causes:
i. โ :โ premenopausal + โ-specific factors (๐คฐ๐ป + hormonal influences)
ii. โ : older population
c. DIFF โ DX challenges + TTO uncertainty + underrepresentation in clinical trial.
d. mm โฉ
i. cause-specific TTO
ii. ๐ค โ-specific risks
iii. more-agressive lifetime prevention
3. GL โ ๐ฃ
i. SCAD
ii. MINOCA
iii. LESS COMMON: Atherosclerosis
Monday, September 21, 2026 at 18:15:29 CEST
EQO, BKN, C, KYEC, LP, HIBN, AAQC
โณ TIME MANAGEMENT
01:16:01
Round: 7 02:03:27 Comments
Round: 6 28:58:36 RECAP
Round: 5 14:39:15 Interpretation
Round: 4 11:00:40 Reading + notes
Round: 3 04:51:69 ART selection
Round: 2 00:39:52 Comments
Round: 1 13:49:41 Past JR
i. Could miss โ SCAD + plaque erosion
ii. So โ do INTRACORONARY imaging + multimodality imaging.
i. Standard GL-directed medical TTO โ๏ธ โ youngโ
ii. For SCAD
1. PCI โ๏ธ
2. DAPT โ๏ธ
3. Conservative โ๏ธ
iii. DAPT
1. PCI
2. plaque disruption
3. โ๏ธ : SCAD โ vasospastic MECHS
iv. B-blockers
1. MINOCA to prevents recurrence.
i. Aggressive. Why? long lifetime risk in premenopausal โ
ii. LDL โ <55-70
iii. SAP โ <120, if tolerated
iv. โ-specific rf:
4. RATIONALE.
a. Not simply a โearly atherosclerosisโ
b. Earlier + more-aggresive LIFETIME risk โ
c. Evidence gaps (mm largely empirical):
i. SCAD
ii. MINOCA
d. โnoncardiac chest painโ โ ID properly
5. SOURCE โถ๏ธ Kovacic JC, et al. Acute coronary syndromes in premenopausal women: A scientific statement from the American Heart Association. Circulation 2026 Feb 17; 153:e89. DOI: 10.1161/CIR.0000000000001416.
2026 BMJ - Early treatment with rasburicase + risk of KRT + death in adults w_ TLS (Shenoy) [R].pdf
Codified by KYEC
DHL = lactate dehydrogenase, RRT= renal replacement therapy, โ = association
TLS = tumor lysis syndrome
ADM = admission
1. ๐๐๐พ ๐จ๐๐ค๐ฅ๐ โถ๏ธ ๐๐๐พ ๐จ๐๐ค๐ฅ๐ โถ๏ธ 2026, BMJ, USA ๐บ๐ธ โ emul_TargetTrial โ <1500 (36 US H+) โ 2014-2023 (9a) โ P I C O:
2. EVIDENCE.
a. TLS โ life threatening oncological EMERGENCY
b. Results from the TUMOR CELLS + TTO
c. MECH โ โK, โphophate, โnucleic acids โ uric acid
d. Crystals in tubules โ due to poorly soluble at low pH โฉ AKI + MM + mm
e. Rasburicase โ prophylaxis + TTO
f. ๐ ธ converts โฉ uric acid โ allantoin
g. Clinical OC โ NO STUDY
h. FDA โ approved for children + adults โฉ small RCT
i. โ uric acid
ii. no โ๏ธ MM + AKI
i. Evidence for prophylaxis PRIMARILY
3. METHODS.
- metastasis
- โ tumor burden
- LAB + clinical features (TLS)
- ACTIVE hematological malignancy (known or suspected) โ metastasis
- โ tumor burden
- WBC >50, โ
- DHL >3x ULN
Monday, September 28, 2026 at 18:10:59
EQO, MJLD, LCO, KYEC, LP, HIBN, AAQC
- LABs
- Uric acid >8, โ
- At least 1/3: ( within 24h โโhyperuricemiaโโ)
- K >6
- tCa <1,75, iCa <1,12
- PO4 >1,45
- Clinical findings
4. RESULTS.
a. Received ๐ ธ
i. 55%
b. Administration time
i. 5h
c. Uric acid (mg/dL)
i. ๐
ธ 12
ii. ๐
ฒ 10
d. Severity โ well balanced (inverse probability)
e. pOC (p<0.001)
i. ๐ ธ 33%
ii. ๐ ฒ 42%
iii. โ 1/3 lower r w_๐ ธ
f. ยฎ consistent โ sOC
5. SOURCE โถ๏ธ Shenoy T, Sanchez-Almanzar D, Dias JA, et al. Early treatment with rasburicase and risk of kidney replacement therapy and death in adults with tumour lysis syndrome: emulated target trial. BMJ. 2026;394:e100040. Published 2026 Jul 23. doi:10.1136/bmj-2026-100040
โณ TIME MANAGEMENT
01:15:16
Round: 8 05:03:26 Comments
Round: 7 23:32:76 Methods
Round: 6 10:17:72 Interpretation
Round: 5 15:02:89 Intro
Round: 4 07:09:52 Interpretation
Round: 3 04:49:09 Reading + notes
Round: 2 05:07:86 ART selectionRound: 1 07:57:68 Past JR
2026 NEJMc - Does Initial Diuretic Dose Matter in HF Exacerbation (JAHA).pdf
Codified by SLDC
BID = bis in die, CREA = creatinine, DEF = definition, HF = heart failure, LOS = length of stay
1. ๐๐๐พ ๐จ๐๐ค๐ฅ๐ โถ๏ธ 2026, JAHA, USA ๐บ๐ธ โ retros โ >14k (24H+) โ โ โ P I C O:
- < home dose = G1
- = home dose = G2
- > home dose = G3
2. EVIDENCE.
a. DOSE trial
i. 2011, NEJM, USA ๐บ๐ธ โ RCT โ 308 โ โ โ P I C O:
1. ๐ ฟ decompensated HF โ decompensated โคน 24h โ chronic HF โ diuretic at home โคน month
2. ๐ ธ furo bolus โค furo high-dose
3. ๐ ฒ furo infusion โค furo low-dose
4. ๐ พ
a. pOC: efficacy = symtomps 72h, safety = creatinine 72h,
b. sOC โฉ H+ LOS, H+ readmission
ii. ยฎ ๐ก๐ข ๐๐๐๐
iii. SYMPTOMS โฉ โ (numeric) in high-dose (p=0.06)
1. โ diuresis
2. โ weight loss
iv. CREATININE โฉ โ in high-dose (p=0.04)
v. Bolus ๐ continuous โฉ ๐ก๐ข ๐๐๐๐
vi. sOC โฉ ๐ก๐ข ๐๐๐๐
vii. SOURCE โถ๏ธ Felker GM et al for the NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011 Mar 3; 364:797.
Thursday, October 1, 2026 at 18:20:22 CEST
EQO, MJLD, LCO, RCH, KYEC, LP, HIBN, AAQC
3. METHODS.
- not taking loop diuretics at home
- using thiazides
4. RESULTS.
a. 3 groups
i. < home dose โฉ 13%
ii. = home dose โฉ 22%
iii. > home dose โฉ 65%
b. LOS (p<0.05)
i. G1 = 5d
ii. G2 โ G3 = -0.5d โ -0.7d
c. READMISSIONS (<0.05)
i. G1 + G2 โฉ 18%
ii. G3 โฉ 15%
d. AKI (DEF. โCREA >0.3)
i. G3 โฉ more common
ii. G2
e. MM
i. G1, G2, G3 โฉ ๐ก๐ข ๐๐๐๐
5. RATIONALE.
a. Underdosing is due to:
i. incorrect dose-conversion
ii. lack of dose-conversion
b. How to adjust?
i. Step 1. Torsemide โ bumetanide โ convert to โ furo-equivalent home dosing
ii. Step 2. Torsemide x 2 โค bumetanide x 2,5
iii. Step 3. Usually BID while in H+
c. โ I also tolerate a small bump in creatinine level, as long as Iโm
seeing good diuresis and weight loss. (Daniel Dressler)
6. SOURCE โถ๏ธ 6. Qadri N, et al. Cohort study of initial diuretic dosing and outcomes among patients hospitalized for congestive heart failure: Insights from the Cardiovascular Quality Improvement and Care Innovation Consortium. J Am Heart Assoc 2026 Mar 17;
15:e038783. DOI: 10.1161/JAHA.124.038783.
โณ TIME MANAGEMENT
01:20:13
Round: 7 05:33:52 Comments
Round: 6 35:22:28 RECAP
Round: 5 07:23:50 DOSE
Round: 4 09:50:69 โ interpretation
Round: 3 03:12:64 Reading + notes
Round: 2 07:54:67 ART selection
Round: 1 10:56:11 Past JR
2026 Clin Microbiol Infect - Duration of antibiotic therapy f_ bacteraemia in immune compromised hosts (Hamani) [R].pdf
Codified by KYEC
โR = highly resistant, โimm = immunocompromised, BALANCE = Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness, dMV = duration of mechanical ventilation, fd_ATB = antibiotic-free days, mITT = modified intention-to-treat, MM90 = 90-day mortality, secINF = secondary infections
ร = adverse events
1. ๐๐๐พ ๐จ๐๐ค๐ฅ๐ โถ๏ธ 2026, Clin Microbiol Infect, CA ๐จ๐ฆ โ RCT BALANCE post-hoc โ >1k (>500 each group) โ 2014-2023 (<10y) โ P I C O:
2. METHODS.
1. Neutropenia (<0.5)
2. Transplantation: solid organ โ bone marrow
3. Blood cultures:
a. S. aureus โ S. lugdunensis
b. yeast โ other fungus
c. prostetic ๐ซ valves
d. prolonged ATB duration
i. endocarditis,
ii. osteomyelitis,
iii. septic arthritis,
iv. undrained abscesses, and
v. unremoved prosthetic infection).
- just for SURVIVED โฅ7d
Monday, October 5, 2026 at 18:15:21 CEST
EQO, MJLD, RCH, ASMA, KYEC, JAPG, HIBN, AAQC
3. RESULTS..
a. โ compromised
i. 28%
b. Randomization
i. 7d โ 530
ii. 14d โ 507
c. Most common
i. Solid malignancies 75%
ii. lymphoma 10%
iii. chemotherapy 15%
iv. HIV/AIDS 2,3%
d. Neutropenic
i. small number
ii. 2,5%
e. Days of ATB (median)
i. 8
ii. 14
f. MM90 โ ITT (p=0.16)
i. 7 โ 20%
ii. 14 โ 24%
g. MM90 โ mITT (p=0.18)
i. 7 โ 20%
ii. 14 โ 23%
SOURCE โถ๏ธ Hamani M, Pinto R, Lee TC, et al. Duration of antibiotic therapy for bacteraemia in immune compromised hosts-a post-hoc subgroup analysis of the Bacteremia Antibiotic Length Actually Needed For Clinical Effectiveness (BALANCE) randomized clinical trial. Clin Microbiol Infect. Published online June 9, 2026. doi:10.1016/j.cmi.2026.06.
โณ TIME MANAGEMENT
01:48:58
Round: 10 19:52:78 Comments
Round: 9 13:18:32 Results
Round: 8 06:14:63 MEthods
Round: 7 02:15:10 Interpretation
Round: 6 01:38:13 Intro โ reading + notes
Round: 5 29:47:25 RECAP
Round: 4 09:21:87 Interpretation
Round: 3 04:08:70 Reading + notes
Round: 2 07:13:56 ART selection
Round: 1 15:08:48 Past JC
2026 ICUmmp - Cardiac Output Monitoring Made E.A.S.Y. (+ Only When You Need It) (Michard) [r].pdf
Codified by KYEC
โ HR = bradycardia, โ VOL = hypovolemia, ๐ซ DYSF = cardiac dysfunction, APSF = Anesthesia Patient Safety Foundation, ESAIC = European Society of Anaesthesiology and Intensive Care, hrSx = high-risk surgery, PLR = passive leg raising
1. ๐๐๐พ ๐จ๐๐ค๐ฅ๐ โถ๏ธ 2026, ICUmmp, CH โ r โ NA โ NA โ P I C O:
2. Barriers for clinical adoption
a. lack of access
b. high cost
3. Solution
a. โ๏ธ accessibility โ DIGITAL APP (in the monitor) b. visual decision support โ UNDERLYING MECHS
4. Main point
a. Identify the UNDERLYING CAUSES (root causes):
i. โ VOL
ii. โ HR
iii. ๐ซ DYSF
b. Recommended by:
i. APSF
ii. ESAIC
5. Challenging to distinguish the 3 root causes COMPARED TO bradycardia.
6. PRESSURE ๐ FLOW
a. ๐จ โฉ CO
b. โฐ โฉ MAP
c. โโฐ โ ok ๐จ (N โ โ CO)
i. VASODILATION
d. โโฐ โ โ ๐จ
i. Options:
1. โ VOL
2. ๐ซ DYSF
ii. How to distinguish?
1. fluid challenge
2. PLR
iii. Fluid responder?
1. YES โ โVOL
2. NO โ ๐ซ DYSF
7. Who should we monitor CO โ (ESAIC)
a. hr baseline for complication (rA)
b. hrSx (rB)
8. hrQx patients
a. underused
b. surveys โ observational
9. OBS
a. 23 H+
b. FR ๐ซ๐ท
c. rA
d. CO MONITORING โ 10%
10. large OBS
a. 28 EU nations
b. rB
c. CO MONITORING โ ~10%
Thursday, October 8, 2026 at 18:20:26
EQO, MJLD, RCH, ASMA, KYEC, JAPG, HIBN, AAQC
11. โ GAP โ GL ๐ real-life PRACTICE
12. WHY people do no follow GL?
a. SURVEY 1
i. 2 year ago
ii. ESAIC members
iii. Primary barrier
1. lack of access
2. high cost of tools
b. SURVEY 2
i. WORLDWIDE
ii. 39 nations
iii. middle-income countries
iv. 72% respondents
v. They would use IF they were LESS EXPENSIVEโ๏ธ
13. CO monitoring is EXPENSIVE
a. Cost? โ >50k EUR
b. Pressure sensors โ 100 - 400 EUR per unit
c. Spent when used โ 67 MILLON per year EUR
d. COMPARED TO
i. nurses salaires โ >200 nurses / year
ii. pocket ECHO devices โ >10k
14. ESAIC GL
a. consumable pressure sensors โ 1 billion EUR / year
15. All these considerations apply to โ CIRCULATORY SHOCK (w_AL)
SOURCE โถ๏ธ SOURCE โถ๏ธ Michard F, Lakhal K, Rex S. Cardiac output monitoring made E.A.S.Y. (and only when you need it). ICU Management & Practice. 2026;26(3):177-180.
โณ TIME MANAGEMENT
02:29:16
Round: 6 60:17:72 Comments
Round: 5 15:02:89 Wrap-up
Round: 4 50:09:52 Interpretation
Round: 3 4:49:09 Reading + notes
Round: 2 05:07:86 ART selection
Round: 1 07:57:68 Past JR
2026 NEJMc - Age and Early TAVR for Asymptomatic Aortic Stenosis (Circ Cardiovasc Interv).pdf
Codified by YAPG
โ = recommendation(s), AF = atrial fibrillation, AS = aortic stenosis, CS = clinical surveillance, ind_fun = industry-funded, PD = Parkinsonโs disease, pLVEF = preserved left ventricular ejection fraction, SCAN = somato-cognitive action network, TTO = treatment(s), US = ultrasound
1. ๐๐๐พ ๐จ๐๐ค๐ฅ๐ โถ๏ธ 2026, Circ Cardiovasc Interv, USA ๐บ๐ธ โ ind (Edwads LifeSciences)_fun_ post hoc_ RCT โ 901 (141, 263, 250, 246) โ ฦ-up 5y โ P I C O:
2. EVIDENCE.
a. Original paper:
i. EARLY TAVR โถ๏ธ 2025, NEJM, USA ๐บ๐ธ + CA ๐จ๐ฆ โ pros_mc_ol_RCT โ 901 โ Mar 2017 - Dec 2021 | ฦ-up 5y โ P I C O:
Monday, October 19, 2026 at 17:20:07 WEST
EQO, MJLD, RCH, ASMA, KYEC, JAPG, HIBN, AAQC
1. ยฎ pOC (p<0.001)
a. ๐ ธ 27%
b. ๐ ฒ 45%
2. ยฎ MM (95%CI 0.6-1.44)
a. ๐ ธ 8%
b. ๐
ฒ 9%
3. ยฎ Sโ (95%CI 0.35-1.1)
a. ๐ ธ 4%
b. ๐ ฒ 7%
4. ยฎ unplanned H+ CV-causes (95%CI 0.33-0.55)
a. ๐ ธ 21%
b. ๐ ฒ 42%
3. SOURCE โถ๏ธ Goel K, et al. Age and procedural timing for asymptomatic severe aortic stenosis: Analysis from the EARLY TAVR trial. Circ Cardiovasc Interv 2026 Jun 3; [e-pub].10.1161/CIRCINTERVENTIONS.125.016370. PubMed
โณ TIME MANAGEMENT
02:00:55
Round: 6 46:39:86 RECAP
Round: 5 20:28:89 Interpretation
Round: 4 02:52:88 Reading + notes
Round: 3 05:23:71 ART selection
Round: 2 00:24:24 Comments
Round: 1 16:05:86 Past JR
2026 NEJMc - Age and Early TAVR for Asymptomatic Aortic Stenosis (Circ Cardiovasc Interv).pdf
Codified by YAPG
โ = recommendation(s), AF = atrial fibrillation, AS = aortic stenosis, CS = clinical surveillance, ind_fun = industry-funded, PD = Parkinsonโs disease, pLVEF = preserved left ventricular ejection fraction, SCAN = somato-cognitive action network, TTO = treatment(s), US = ultrasound
1. ...
2. RESULTS.
a. Age โ pOC โ Sโ โ u_H+_HF
i. ๐ก๐ข ๐๐๐๐
b. Sโ โ 65-69y (ฦ-up 5y)
i. ๐ ธ 0% โ๏ธ
c. Sโ โ โฅ80y (ฦ-up 5y)
i. ๐ ธ 4% โ๏ธ
ii. ๐ ฒ 16%
d. H+_HF โ โฅ80y (ฦ-up 5y)
i. ๐
ธ 9% โ๏ธ
ii. ๐
ฒ 19%
Thursday, October 22, 2026 at 18:17:32 CEST
EQO, MJLD, RCH, ASMA, KYEC, JAPG, HIBN, AAQC
3. RATIONALE.
a. FDA approved TAVR for this ๐ ธ
b. Critics
i. lack of SS benefit
ii. โ rate of early conversion to TAVR (87%)
c. REINFORCES NEJM 2025
d. Test RISKS of the POSSIBILITY:
i. of late TAVR failure
ii. HF
iii. urgent TAVR d_CS
e. However, TAVR may reduce:
i. Hospital length of stay.
ii. ICU resource utilization.
iii. Postoperative complications.
iv. Rehabilitation requirements.
v. Readmissions and subsequent healthcare costs.
4. SOURCE โถ๏ธ Goel K, et al. Age and procedural timing for asymptomatic severe aortic stenosis: Analysis from the EARLY TAVR trial. Circ Cardiovasc Interv 2026 Jun 3; [e-pub].10.1161/CIRCINTERVENTIONS.125.016370. PubMed
โณ TIME MANAGEMENT
01:29:16 (estimated)
Round: 9 11:47:81 RECAP
Round: 8 12:03:26 Interpretation
Round: 7 03:32:76 Reading + notes
Round: 6 01:17:72 Comments
Round: 5 15:02:89 Wrap-up
Round: 4 07:09:52 Interpretation
Round: 3 05:49:09 Reading + notes
Round: 2 03:07:86 ART selection
Round: 1 07:57:68 Past JR
2026 NEJMc - Is It Safe to Stop Long Term BB after MI (LANCET).pdf
Codified by YAPG
BB = beta blockers, CHF = chronic heart failure, CVE = cardiovascular event, LVEF = left ventricular ejection fraction, MI = myocardial infarction, nfMI = nonfatal myocardial infarction, nfSโ = nonfatal stroke, PROBE = prospective, randomized, open-label, blinded endpoint, prQOL = patient-reported quality of life, reVASC = revascularization, BB = Beta blockers
1. ๐AO โถ๏ธ 2026, LANCET, โ โ pooled ๐ค โ 6k โ 3,6y (ฦ-up 3y) โ P I C O:
Monday, October 26, 2026 at 18:00:41 CET
EQO, MJLD, RCH, ASMA, KYEC, JAPG, HIBN, AAQC
โณ TIME MANAGEMENT
01:43:58
Round: 6 01:14:26 RECAP
Round: 5 12:22:82 Interpretation
Round: 4 03:00:95 Reading + notes
Round: 3 08:20:16 ART selection
Round: 2 00:15:86 Comments
Round: 1 05:32:03 Past JR
2026 NEJMc - Is It Safe to Stop Long Term BB after MI (LANCET).pdf
Codified by ๐๐๐ผ๐ผ๐๐พ แดฎแดผ (EQO)
ACE-i = angiotensin-converting enzyme inhibitor, AF_H+ = atrial fibrillation hospitalization, antiPLA = antiplatelets, ARB = angiotensin receptor blocker, lr = low risk, MI = myocardial infarction, PCI = percutaneous coronary intervention, pg = parallel-group, safOC = safety outcomes, STEMI = ST-segment elevation myocardial infarction, MI = Myocardial infarction
1. Continuationโฆ
2. EVIDENCE.
a. REDUCE-AMI โถ๏ธ 2024, NEJM, SW ๐ธ๐ช, ES ๐ช๐ช NZ ๐ณ๐ฟ โ reg-emb_pg_ol_RCT โ >5k โ Sep 2017 - May 2023 (6y) โ P I C O
- pOC = Composite: MM โ newMI (โrecurrentโ)
- sOC = MM โ cvMM โ newMI โ AF_H+ โ hf_H+
- safOC = bradycardia โ AVB II or III โ โAP โ syncope โ pacemaker โ asthma or COPD_H+ โ Sโ _H+
Thursday, October 29, 2026 at 18:44:12 CET
EQO, MJLD, RCH, ASMA, KYEC, JAPG, HIBN, AAQC
โณ TIME MANAGEMENT
01:40:16
Round: 6 2:17:72 Comments
Round: 5 25:02:89 RECAP
Round: 4 20:09:52 Interpretation
Round: 3 05:49:09 Reading + notes
Round: 2 10:07:86 Continuation
Round: 1 07:57:68 Past JR
2026 NEJMc - Is It Safe to Stop Long Term BB after MI (LANCET).pdf
Codified by YAPG
๐ = arrhythmia, AF = atrial fibrillation, IND = indication, l-tBB = long-term beta blocker, ni = noninferiority, PD = Parkinsonโs disease, SCAN = somato-cognitive action network, STEMI = ST-segment elevation myocardial infarction, TTO = treatment(s)
๐ = arrhythmia;
1. ๐AO โถ๏ธ 2026, LANCET, โ โ pooled ๐ค โ 6k โ 3,6y (ฦ-up 3y) โ P I C O:
2. EVIDENCE.
a. ABYSS 2024
b. REDUCE-AMI 2024
c. SMART-DECISION โถ๏ธ 2026, NEJM, KR ๐ฐ๐ท โ ol_ni_RCT โ >2,5k โ Apr 2021 - Apr 7 2023 (2y) โ P I C O
- ๐ ธ 7,2%
- ๐ ฒ 9%
- ๐ก๐ข ๐๐๐๐
- 2 previous trials already suggested NO CLEAR ACUTE benefit (lr_pxs)
Monday, November 2, 2026 at 18:31:12 CET
EQO, MJLD, RCH, ASMA, KYEC, JAPG, HIBN, AAQC
โณ TIME MANAGEMENT
01:16:05
Round: 9 09:05:51 Comments
Round: 8 12:37:61 RECAP current
Round: 7 24:55:75 Original ART
Round: 6 02:31:44 RECAP
Round: 5 10:18:35 Interpretation
Round: 4 02:33:69 READING + notes
Round: 3 04:28:78 continue... ART
Round: 2 01:23:90 CommentsRound: 1 08:10:30 Past JR